Sarepta Therapeutics, Inc. (SRPT) Analysts See $-0.57 EPS on July, 18

June 27, 2018 - By Estela Ashley

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Corporate Logo
Big Money Sentiment decreased to 0.97 in Q1 2018. It has change of 0.25, from 2017Q4’s 1.22. The ratio turned negative due to Sarepta Therapeutics, Inc. positioning: 31 sold and 81 reduced. 45 funds took holdings and 64 increased holdings. Investors holded 52.88 million in 2017Q4 but now own 54.74 million shares or 3.52% more.
Symphony Asset Management Limited Liability Corporation holds 0.03% or 3,602 shs in its capital. First Tru Advisors Lp reported 51,937 shs. Services Automobile Association, a Texas-based fund reported 9,454 shs. 24,700 are owned by Savings Bank Of Nova Scotia. Canada Pension Plan Invest Board accumulated 15,800 shs. 19,197 are held by Metropolitan Life Ins Company Ny. Alliancebernstein Ltd Partnership reported 0.01% of its capital in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Sectoral Asset stated it has 327,698 shs or 2.66% of all its holdings. Comerica State Bank holds 0.01% or 16,202 shs. Mutual Of America Cap Mgmt Limited owns 950 shs or 0% of their US capital. Td Asset Management holds 0.01% of its capital in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 70,900 shs. Legal & General Gp Public Limited Co owns 25,080 shs. Vanguard accumulated 0.02% or 5.15M shs. Swiss National Bank accumulated 106,500 shs or 0.01% of the stock. Marshall Wace Llp accumulated 0.02% or 7,988 shs.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is awaited to reveal earnings on July, 18., as reported by Faxor. The earnings per share diference is $0.58 or 50.43 % up from last years number. Previous year: $-1.15; Analysts forcast: $-0.57. 29.55 % negative EPS growth is what analysts predict. $-0.44 earnings per share was announced for last quarter. The stock decreased 3.69% or $5 during the last trading session, hitting $130.53.Currently Sarepta Therapeutics, Inc. is uptrending after 197.08% change in last June 27, 2017. SRPT has also 768,120 shares volume. SRPT outperformed by 184.51% the S&P500.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

In total 20 analysts cover Sarepta Therapeutics (NASDAQ:SRPT). “Buy” rating has 18, “Sell” are 0, while 2 are “Hold”. (NASDAQ:SRPT) has 90% bullish analysts. 36 are the (NASDAQ:SRPT)’s ratings reports on Jun 27, 2018 according to StockzIntelligence Inc. On Friday, February 9 the stock has “Buy” rating by Piper Jaffray. On Friday, May 4 Morgan Stanley maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) with “Equal-Weight” rating. On Friday, May 11 Barclays Capital upgraded Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to “Overweight” rating. The company rating was maintained by Robert W. Baird on Thursday, June 21. In Monday, March 12 report H.C. Wainwright maintained the stock with “Buy” rating. On Tuesday, June 5 the stock has “Buy” rating by Nomura. On Friday, January 19 the rating was maintained by Leerink Swann with “Buy”. On Wednesday, March 14 JP Morgan maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) with “Overweight” rating. On Tuesday, May 15 the rating was maintained by Leerink Swann with “Buy”. On Thursday, March 15 the rating was maintained by SunTrust with “Buy”.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases.The firm is worth $8.55 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.Last it reported negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

For more Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news posted briefly go to: Fool.com, Seekingalpha.com, Fool.com, Nasdaq.com or Fool.com. The titles are as follows: “Is Sarepta Therapeutics Stock Headed to Over $200 a Share?” posted on June 21, 2018, “Sarepta Therapeutics: Chasing The Good News” on June 21, 2018, “Are These 3 Red-Hot Gene Therapy Stocks Still Buys?” with a publish date: June 25, 2018, “Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday” and the last “3 Biotech Stocks That Soared This Week: Are They Buys?” with publication date: June 23, 2018.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.